Mechanisms of Action Appetite suppression: GLP-1 acts on hypothalamic receptors to reduce hunger signals and increase satiety, a central mechanism covered in semaglutide training for physicians Gastric emptying delay: Slows the rate at which food leaves the stomach, prolonging the feeling of fullness Insulin secretion enhancement: Stimulates glucose-dependent insulin secretion from pancreatic beta cells Glucagon suppression: Reduces glucagon secretion, contributing to improved glycemic control Central reward pathway modulation: Emerging research suggests GLP-1 agonists may reduce food cravings by acting on brain reward centers Semaglutide is an acylated GLP-1 analog with a 94% structural homology to native human GLP-1
More significant appetite suppression
PlexusDx Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), making it accessible without insurance or membership fees
According to the October 2024 multi-society guidance from the American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), most patients can safely continue their GLP-1 medications before elective procedures with appropriate risk mitigation strategies
However, this data comes from observational studies, not randomized controlled trials, so it should be interpreted cautiously
It releases hormones and inflammatory proteins
